TY - JOUR
T1 - Transplantation of neural progenitor cells into the human CNS
AU - Okano, Hideyuki
N1 - Funding Information:
The present study was supported by the Japan Agency for Medical Research and Development (AMED; grant no. JP22bm0204001 ). I sincerely thank Satoru Morimoto, Momotaro Kawai, Takahiro Kitagawa, Kentaro Ago, and Narihito Nagoshi for their help in preparing the manuscript.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/11
Y1 - 2022/11
N2 - The development of regenerative medicine for spinal cord injury (SCI) and intractable diseases of the nervous system using neural progenitor cells (NPCs) has shown great promise, and several clinical trials have begun. In addition, ex vivo gene therapy using genetically engineered NPCs was recently initiated in the clinical setting by Baloh et al., putatively showing enhanced therapeutic effects. Thus, the era of next-generation NPC transplantation therapy is beginning to dawn.
AB - The development of regenerative medicine for spinal cord injury (SCI) and intractable diseases of the nervous system using neural progenitor cells (NPCs) has shown great promise, and several clinical trials have begun. In addition, ex vivo gene therapy using genetically engineered NPCs was recently initiated in the clinical setting by Baloh et al., putatively showing enhanced therapeutic effects. Thus, the era of next-generation NPC transplantation therapy is beginning to dawn.
KW - ALS
KW - chemogenetics
KW - engineered neural progenitor cells
KW - ex vivo gene therapy
KW - GDNF
KW - spinal cord injury (SCI)
UR - http://www.scopus.com/inward/record.url?scp=85139344085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139344085&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2022.09.009
DO - 10.1016/j.molmed.2022.09.009
M3 - Short survey
C2 - 36182630
AN - SCOPUS:85139344085
VL - 28
SP - 897
EP - 899
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
SN - 1471-4914
IS - 11
ER -